1. Home
  2. LEGN vs GKOS Comparison

LEGN vs GKOS Comparison

Compare LEGN & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Legend Biotech Corporation

LEGN

Legend Biotech Corporation

N/A

Current Price

$19.59

Market Cap

5.9B

Sector

Health Care

ML Signal

N/A

Logo Glaukos Corporation

GKOS

Glaukos Corporation

N/A

Current Price

$103.57

Market Cap

6.9B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
LEGN
GKOS
Founded
2014
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
6.9B
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
LEGN
GKOS
Price
$19.59
$103.57
Analyst Decision
Buy
Strong Buy
Analyst Count
14
14
Target Price
$63.46
$133.07
AVG Volume (30 Days)
2.0M
666.0K
Earning Date
01-01-0001
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$507,442,000.00
Revenue This Year
$67.56
$23.39
Revenue Next Year
$43.20
$27.46
P/E Ratio
N/A
N/A
Revenue Growth
N/A
32.33
52 Week Low
$16.24
$73.16
52 Week High
$45.30
$130.23

Technical Indicators

Market Signals
Indicator
LEGN
GKOS
Relative Strength Index (RSI) 55.82 34.64
Support Level $16.24 $81.54
Resistance Level $21.58 $103.63
Average True Range (ATR) 0.91 3.70
MACD 0.20 -1.68
Stochastic Oscillator 51.70 12.23

Price Performance

Historical Comparison
LEGN
GKOS

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: